Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis

Overview

Journal Indian J Dermatol

Specialty Dermatology

Date 2023 Mar 3

PMID 36865872

Authors

Mahendra M Kura

Anmol Sodhi

Avinash Sajgane

Ashish Karande

Affiliations

Soon will be listed here.

Abstract

Generalised pustular psoriasis (GPP) is an uncommon, severe, life-threatening variant of psoriasis requiring careful therapeutic approach. Conventional treatment modalities have unsatisfactory outcomes, poor side effect profiles and toxicities that have led to an emerging use of biological therapies. Itolizumab, an anti-CD-6 humanised monoclonal IgG1 antibody, is approved for the management of chronic plaque psoriasis in India. We share our experience of using this drug in three cases of GPP that were failing conventional therapies. Its upstream effect on co-stimulatory pathway in disease pathogenesis is the postulated mechanism. Our experience warrants further large-scale exploration of the role of itolizumab in the management of GPP, which would benefit this severely affected population of patients. Although the definite pathogenesis of GPP is unknown fully, molecules blocking CD-6, which plays a role in the interaction between T cells and antigen-presenting cells (APCs), are expected as new promising treatment options for GPP.

Citing Articles

Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.

Puig L, Fujita H, Thaci D, Zheng M, Hernandez Daly A, Leonardi C Dermatol Ther (Heidelb). 2024; 14(9):2331-2378.

PMID: 39088126 PMC: 11393368. DOI: 10.1007/s13555-024-01230-z.

References

Onoufriadis A, Simpson M, Pink A, Di Meglio P, Smith C, Pullabhatla V . Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011; 89(3):432-7. PMC: 3169817. DOI: 10.1016/j.ajhg.2011.07.022. View

Alonso-Ramirez R, Loisel S, Buors C, Pers J, Montero E, Youinou P . Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases. Arthritis. 2011; 2010:130646. PMC: 3195340. DOI: 10.1155/2010/130646. View

Ogawa M, Baughman R, CLENDENNING W . Generalized pustular psoriasis. Arch Dermatol. 1969; 99(6):671-3. View

Nair P, Melarkode R, Rajkumar D, Montero E . CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol. 2010; 162(1):116-30. PMC: 2990937. DOI: 10.1111/j.1365-2249.2010.04235.x. View

Feiwel M, Ferriman D . Impetigo herpetiformis. Proc R Soc Med. 1957; 50(6):392-4. View

Dogra S, Uprety S, Suresh S . Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Expert Opin Biol Ther. 2017; 17(3):395-402. DOI: 10.1080/14712598.2017.1279601. View

Gooderham M, Van Voorhees A, Lebwohl M . An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019; 15(9):907-919. DOI: 10.1080/1744666X.2019.1648209. View

Liang Y, Xing X, Beamer M, Swindell W, Sarkar M, Roberts L . Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders. J Allergy Clin Immunol. 2016; 139(4):1217-1227. PMC: 5385276. DOI: 10.1016/j.jaci.2016.10.021. View

Ogawa E, Sato Y, Minagawa A, Okuyama R . Pathogenesis of psoriasis and development of treatment. J Dermatol. 2017; 45(3):264-272. DOI: 10.1111/1346-8138.14139. View

10.

Risum G . Psoriasis exacerbated by hypoparathyroidism with hypocalcaemia. Br J Dermatol. 1973; 89(3):309-12. DOI: 10.1111/j.1365-2133.1973.tb02980.x. View

11.

Furue K, Yamamura K, Tsuji G, Mitoma C, Uchi H, Nakahara T . Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis. Acta Derm Venereol. 2017; 98(1):5-13. DOI: 10.2340/00015555-2808. View

12.

Yamasaki K, Nakagawa H, Kubo Y, Ootaki K . Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2016; 176(3):741-751. DOI: 10.1111/bjd.14702. View

13.

Johnston A, Xing X, Wolterink L, Barnes D, Yin Z, Reingold L . IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017; 140(1):109-120. PMC: 5494022. DOI: 10.1016/j.jaci.2016.08.056. View

14.

Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H . Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003; 295 Suppl 1:S43-54. DOI: 10.1007/s00403-002-0371-6. View

15.

Krupashankar D, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy T . Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014; 71(3):484-92. DOI: 10.1016/j.jaad.2014.01.897. View

16.

Baker H, Ryan T . Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968; 80(12):771-93. DOI: 10.1111/j.1365-2133.1968.tb11947.x. View

17.

Menon R, David B . Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2015; 8:215-22. PMC: 4407739. DOI: 10.2147/CCID.S47784. View